Page last updated: 2024-11-08

methylsulfonyl benzothiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methylsulfonyl benzothiazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID242777
CHEMBL ID4851001
SCHEMBL ID2754297
MeSH IDM0578737

Synonyms (31)

Synonym
BIDD:GT0729
2-(methylsulfonyl)benzothiazole
EN300-23757
2-methanesulfonyl-1,3-benzothiazole
nsc51671
7144-49-2
nsc-51671
benzothiazole, 2-(methylsulfonyl)-
inchi=1/c8h7no2s2/c1-13(10,11)8-9-6-4-2-3-5-7(6)12-8/h2-5h,1h
TIMTEC1_004950
HMS1548A22
2-methylsulfonyl-1,3-benzothiazole
AKOS001288035
2-(methylsulfonyl)-1,3-benzothiazole
2-(methylsulfonyl)benzo[d]thiazole
5P-344S
2-methanesulfonylbenzothiazole
YZOXPLQWARQVEJ-UHFFFAOYSA-N
SCHEMBL2754297
mfcd00142947
2-(methanesulfonyl)-1,3-benzothiazole
DTXSID10287587
CCG-255317
methylsulfonyl benzothiazole
benzothiazole,(methylsulfonyl)-
73544-94-2
CS-0210224
AMY32488
A935519
F83040
CHEMBL4851001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1763223Thiol reactivity of the compound assessed as compound-TNB2 complex formation using DTNB at 200 uM measured after 1 hr by high-throughput thiol reactivity assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of selective fragment-sized immunoproteasome inhibitors.
AID1763211Inhibition of human chymotrypsin-like beta 5i subunit of iCP assessed as residual activity using suc-LLVY-AMC as flurogenic substrate at 100 uM for 90 mins by fluorescence-based assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of selective fragment-sized immunoproteasome inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.18 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]